Journal
MEDICAL CLINICS OF NORTH AMERICA
Volume 97, Issue 3, Pages 363-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.mcna.2013.01.001
Keywords
International Work Group; Alzheimer disease; Diagnosis; Biomarkers
Categories
Funding
- Pfizer
- Eisai
- MSD
- Merz
- Janssen-Cilag
- Novartis
- Lundbeck
- Roche
- Bayer
- Bristol-Myers Squibb
- GE Health Care
- GlaxoSmithKline
- Innogenetics
- Merck
- Genentech
- Nutricia
- Janssen Al
- Avid-Lilly
Ask authors/readers for more resources
Alzheimer-type biomarker changes are identifiable in asymptomatic and mildly symptomatic predementia phases of Alzheimer disease (AD) and AD dementia. The International Work Group (IWG) guidelines for diagnosis identify a unified spectrum of 3 phases. The classic clinical feature that indicates AD is an episodic memory defect of the amnestic type. IWG criteria require biomarker support for the diagnoses of AD at any clinical stage. Pathophysiologic and topographic biomarkers are recognized. These criteria are proposed to allow highly specific diagnosis of AD and assist in identifying patients for clinical trials of AD-related treatments and other types of AD research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available